טוען...
Relapsing-Remitting Multiple Sclerosis Patients' Experience with Natalizumab: A Phenomenological Investigation
This phenomenological investigation was undertaken to gain a better understanding of multiple sclerosis (MS) patients' experience with natalizumab (Tysabri; Biogen Idec Inc, Cambridge, MA) treatment and its impact on their quality of life (QOL). Twenty MS patients who were receiving natalizumab...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Consortium of Multiple Sclerosis Centers
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3882975/ https://ncbi.nlm.nih.gov/pubmed/24453731 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073-14.1.39 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|